- Abstract:
-
As of September 30, 2015, a total of 1589 laboratory-confirmed cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization (WHO). At present there is no effective specific therapy against MERS-CoV. The use of convalescent plasma (CP) has been suggested as a potential therapy based on existing evidence from other viral infections. We aim to study the feasibility of CP therapy as well as its safety and clinical and labo...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Publisher:
- SpringerPlus Publisher's website
- Journal:
- SpringerPlus Journal website
- Volume:
- 4
- Issue:
- 709
- Publication date:
- 2015-10-19
- Acceptance date:
- 2015-10-29
- DOI:
- ISSN:
-
2193-1801
- Pubs id:
-
pubs:579327
- URN:
-
uri:e662c4fd-edb1-4dbf-9d5e-94328d9e917e
- UUID:
-
uuid:e662c4fd-edb1-4dbf-9d5e-94328d9e917e
- Local pid:
- pubs:579327
- Paper number:
- 709
- Language:
- English
- Keywords:
- Copyright holder:
- Yaseen Arabi et al.
- Copyright date:
- 2015
- Notes:
- This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Journal article
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
Actions
Authors
Funding
Wellcome Trust
More from this funder
World Health Organization
More from this funder
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record